Important Federal Workplace D&A Testing Panel Changes

Posted by: Jenny Sloan

Effective October 1, 2017, the Department of Health and Human Services (HHS) will implement changes to the current Federal Workplace Drug Testing requirements.

The HHS guideline revisions will include the following changes:

  • Expand urine drug testing panel to include four Schedule II drugs: Hydrocodone, Hydromorphone, Oxycodone, and Oxymorphone
  • Remove MDEA for confirmatory testing
  • Raise the lower pH cutoff from 3 to 4 to identify an adulterated specimen
  • Allow a Medical Review Officer (MRO) to recommend the collection of an oral fluid specimen in certain situations, as permitted by agency policy 

More information can be found at the following link:

Feel free to reach out to TPS Alert at (918) 970-4990 or via email to for any questions.